Thomas Lynch Jr. Acquires 1,905 Shares of Natera, Inc.

Thomas Lynch Jr., an insider at Natera, Inc. (NasdaqGS: NTRA), purchased 1,905 shares of the company on June 26, 2026. The transaction was not part of a planned purchase program. This insider activity comes as shares of the diagnostics company traded around $267.05 on Wednesday.

Insider Buying and Selling at Natera, Inc.

On June 26, 2026, Thomas Lynch Jr. acquired 1,905 shares of Natera, Inc. Other insiders also made similar moves on the same day. Roy Baynes bought 1,646 shares, Eric Rubin added 75 shares, and Roelof Botha purchased 1,691 shares. Additionally, Rowan Chapman acquired 1,674 shares, and Gail Boxer Marcus bought 1,669 shares.

Other Institutional Activity in Natera, Inc.

Several institutional investors have been active in Natera, Inc. recently. JPMorgan Chase & Co increased its holdings by 532,333 shares, bringing its total to 13,386,667 shares valued at approximately $2.5 billion, a 4.1% increase. Price T Rowe Associates Inc. added 1,312,887 shares, growing its stake by 12.1% to 12,184,876 shares worth about $2.44 billion. BlackRock, Inc. reduced its position slightly by 182,103 shares, ending with 10,677,338 shares valued at $2.14 billion, a 1.7% decrease. Meanwhile, Vanguard Capital Management LLC and Vanguard Portfolio Management LLC both opened new positions with 6,008,496 shares and 5,644,695 shares, respectively.

Natera, Inc. Stock Down 17.1%

Natera, Inc. has a market capitalization of $37.5 billion. The company is not currently profitable, with a forward P/E ratio not meaningful due to negative earnings of -$1.62 per share. The stock's beta is 1.544, indicating volatility higher than the market. Over the past 52 weeks, shares have ranged from $131.81 to $271.47. The 50-day moving average is $212.40, and the 200-day moving average is $208.58. Natera maintains a current ratio of 2.96 and a quick ratio of 2.70, with a debt-to-equity ratio of 13.53.

Recent Earnings

In its latest earnings report, Natera, Inc. posted revenue of $2.5 billion, reflecting a growth rate of 38.8%. Despite the revenue increase, the company reported a net margin of -9.05% and a return on equity of -15.02%. The next earnings announcement is expected on August 6, 2026.

Analysts Set New Price Targets

Analysts have been actively updating their views on Natera, Inc. On June 29, 2026, Guggenheim maintained a buy rating with a price target of $290. Bernstein reiterated its buy rating with a target of $310 on June 26, 2026. BTIG maintained a buy rating with a target of $275 on June 24, 2026, while Barclays also maintained a buy rating with a $260 target on the same day. Overall, the stock has a strong buy consensus with a mean target price of $262.67 based on 21 analyst opinions.

About Natera, Inc.

Natera, Inc. is a healthcare company specializing in diagnostics and research, headquartered in Austin, Texas. The company develops and commercializes molecular testing services, including personalized ctDNA blood tests for cancer monitoring, non-invasive prenatal tests, and various screening tests for hereditary conditions. Led by CEO Steven Leonard Chapman, Natera employs over 6,000 people and collaborates with partners like BGI Genomics and Diakonos Oncology Corp.

Bottom Line

Insider purchases at Natera, Inc., including those by Thomas Lynch Jr., highlight ongoing interest in the company from its leadership. Investors often track insider buys as potential indicators of confidence in a company's future prospects. However, it's important to remember that insider transactions are just one of many factors to consider when evaluating a stock. These transactions are disclosed after the fact and may not reflect the most current sentiment. As always, investors should perform their own due diligence.